CD19 and diffuse large B-cell lymphoma: The results with relma‐cel demonstrate similar preliminary response rates and PK profiles while providing the potential for an improved toxicity profile in heavily‐pre‐treated patients with r/r DLBCL having poor risk features relative to other CD19‐specific CAR‐Ts approved in the US and EU.